Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097659 | 0.95 | HDAC8 (0.50) | ESR2HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL2096234 | 0.92 | HTT (0.48) | ESR2HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL2095015 | 0.92 | HTT (0.48) | ESR2HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL346890 | 0.92 | HTT (0.48) | ESR2HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL2094892 | 0.89 | ESR2 (0.46) | ESR2HDAC1HDAC8HDAC6ESR1 | |
| SCHEMBL5886587 | 0.86 | ESR2 (0.56) | ESR2HDAC1HDAC8HDAC6ESR1 | |
| SCHEMBL5148273 | 0.83 | ESR2 (0.60) | ESR2HDAC1HDAC8HDAC6ESR1 | |
| SCHEMBL781509 | 0.80 | HDAC1 (0.54) | ESR2HDAC1HDAC8HDAC6ESR1 | |
| SCHEMBL4400574 | 0.78 | ESR2 (0.63) | ESR2HDAC1HDAC8HDAC6ESR1 | |
| SCHEMBL6275125 | 0.77 | HDAC8 (0.52) | ESR2HDAC1HDAC8HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023190472-A1 | CYCLOHEXYLENEDIAMINIUM SALT, USE THEREOF, AND MSE TYPE ZEOLITE OBTAINED USING SAME | 公益財団法人相模中央化学研究所 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023282236-A1 | RARE EARTH COMPLEX | 東ソー株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-10988494-B2 | Europium complex | TOSOH CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200354389-A1 | EUROPIUM COMPLEX | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2020-11-12 | — | — | US | disclosed |
| CN-111406059-A | Europium complexes | 东曹株式会社 | 2020-07-10 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ESR2 338/4885HDAC1 280/4885HDAC8 1199/4885 |
| US-10988494-B2 | Europium complex | SSB, XPA, UACA | ESR2 62/4885HDAC1 1056/4885HDAC8 2845/4885 |
| US-20200354389-A1 | EUROPIUM COMPLEX | SSB, XPA, UACA | ESR2 62/4885HDAC1 1056/4885HDAC8 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.